Allogeneic cell therapy isn’t dead, with Brian Culley

So far, allogeneic, or “off the shelf”, cell therapy has failed to produce the kinds of results that autologous cell therapy has. But biotechs haven’t given up on allo, which promises easier distribution and administration than therapies that require modifying cells at the bedside.

At Lineage Cell Therapeutics, CEO Brian Culley has been working for many years on allogeneic cell therapies across a range of indications, the most far along being a potentially practice-changing therapy for macular degeneration.  

In an interview on the sidelines of JP Morgan in San Francisco, Culley described how he sees allogeneic cell therapy creating huge opportunities, even beyond the traditional cell therapy realm of oncology. 

Speaking with pharmaphorum’s Jonah Comstock, he talks about his company’s long history in the space, their approach to allogeneic cell therapy including how they avoid rejection, and the data they have coming up in 2026 about their lead product. 

Culley also reflects on the mood at the show and what he’s been hearing around Union Square. All this and more in the full video below.